Correction: CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression

更正：CLN-978 是一种新型的半衰期延长的 CD19/CD3/HSA 特异性 T 细胞衔接抗体构建体，对 CD19 低表达的 B 细胞恶性肿瘤具有强效活性。